{'fraction_non_alphanumeric': 0.03687445127304653, 'fraction_numerical': 0.021949078138718173, 'mean_word_length': 5.0638297872340425, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Increased serum concentrations of secretory leukoprotease inhibitor in patients with primary Sjögren's syndrome.

BACKGROUND
Secretory leukoprotease inhibitor (SLPI), a 12 kDa serine antiprotease, is produced by serous cells including salivary and lacrimal glands.


OBJECTIVE
We sought to assess whether serum levels of SLPI in patients with primary Sjogren's syndrome (SS) are elevated and correlated with conventional and laboratory indices of disease activity.


PATIENTS AND METHODS
SLPI levels were determined by ELISA of serum from 21 primary SS, and 26 age-matched normal controls.


RESULTS
Increased SLPI concentrations were found in primary SS patients (p < 0.01). Serum SLPI levels were positively correlated with the duration of the disease (r = 0.517, p < 0.025), but not with age, erythrocyte sedimentation rate, CRP, immunoglobulins, number of extraglandular manifestations and saliva production. SLPI levels were also positively correlated with serum levels of beta 2-microglobulin (r = 0.607, p < 0.01).


CONCLUSION
Determination of serum SLPI may provide a new simple noninvasive technique for evaluation of primary SS.